BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 27345638)

  • 21. Long-term follow-up of survival in Hodgkin's lymphoma.
    Canellos GP; Niedzwiecki D; Johnson JL
    N Engl J Med; 2009 Dec; 361(24):2390-1. PubMed ID: 20007568
    [No Abstract]   [Full Text] [Related]  

  • 22. Predictive value of (18)F-FDG hybrid PET/CT for the clinical outcome in patients with non-Hodgkin's lymphoma prior to and after autologous stem cell transplantation.
    Qiao W; Zhao J; Wang C; Wang T; Xing Y
    Hematology; 2010 Feb; 15(1):21-7. PubMed ID: 20132658
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term follow-up of Hodgkin's disease trial.
    Canellos GP; Niedzwiecki D
    N Engl J Med; 2002 May; 346(18):1417-8. PubMed ID: 11986425
    [No Abstract]   [Full Text] [Related]  

  • 24. Management of advanced, resistant Hodgkin's disease and non-Hodgkin's lymphoma: a phase II study.
    Williams SF; Ultmann JE; Gaynor E; Watson S
    Cancer Treat Rep; 1986 Aug; 70(8):1033-4. PubMed ID: 2425964
    [No Abstract]   [Full Text] [Related]  

  • 25. [The choice of chemotherapy under PET/CT-guided treatment de-escalation has a significant impact on fertility and quality of life in young Hodgkin's lymphoma patients].
    Guninski RS; Balermpas P
    Strahlenther Onkol; 2022 Aug; 198(8):752-754. PubMed ID: 35459961
    [No Abstract]   [Full Text] [Related]  

  • 26. Hodgkin's disease--clinical trials and travails.
    DeVita VT
    N Engl J Med; 2003 Jun; 348(24):2375-6. PubMed ID: 12802021
    [No Abstract]   [Full Text] [Related]  

  • 27. First reported case of disease: peliosis hepatis as cardinal symptom of Hodgkin's lymphoma.
    Kleger A; Bommer M; Kunze M; Klaus J; Leithaeuser F; Wegener M; Adler G; Dikopoulos N
    Oncologist; 2009 Nov; 14(11):1088-94. PubMed ID: 19889716
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: a preliminary report.
    Bartlett NL; Rosenberg SA; Hoppe RT; Hancock SL; Horning SJ
    J Clin Oncol; 1995 May; 13(5):1080-8. PubMed ID: 7537796
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Uncommon presentations of Hodgkin's disease. Case 2. Hodgkin's disease of the nasopharynx.
    Hollander SL
    J Clin Oncol; 2004 Jan; 22(1):195-6. PubMed ID: 14701783
    [No Abstract]   [Full Text] [Related]  

  • 30. Hodgkin lymphoma: an Australian experience of ABVD chemotherapy in the modern era.
    Jalali A; Ha FJ; Chong G; Grigg A; Mckendrick J; Schwarer AP; Doig R; Hamid A; Hawkes EA
    Ann Hematol; 2016 Apr; 95(5):809-16. PubMed ID: 26878861
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of PET in Hodgkin's lymphoma and its impact on radiation oncology.
    Kobe C; Dietlein M; Kriz J; Furth C; Fuchs M; Borchmann P; Engert A; Eich HT
    Expert Rev Anticancer Ther; 2010 Sep; 10(9):1419-28. PubMed ID: 20836677
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Will it be another 20 years before Hodgkin lymphoma patients benefit from BEACOPP therapy?
    Diehl V; Engert A
    Nat Clin Pract Oncol; 2006 May; 3(5):227. PubMed ID: 16682982
    [No Abstract]   [Full Text] [Related]  

  • 33. Interim fluoro-2-deoxy-D-glucose-PET predicts response and progression-free survival in patients with Hodgkin lymphoma and HIV infection.
    Okosun J; Warbey V; Shaw K; Montoto S; Fields P; Marcus R; Virchis A; McNamara C; Bower M; Cwynarski K
    AIDS; 2012 Apr; 26(7):861-5. PubMed ID: 22333746
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of a modified Stanford V regimen in patients with advanced Hodgkin's lymphoma.
    Hohaus S; Di Febo A; Storti S; Teofili L; Voso MT; Leone G
    Haematologica; 2004 Jun; 89(6):751-2. PubMed ID: 15194545
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Results of the treatment of Hodgkin's disease stage III and IV using the ABVD and BACOP programs].
    Leszko B; Słomkowski M; Przybyszewska M; Apel D; Pawelski S
    Acta Haematol Pol; 1986; 17(3-4):81-90. PubMed ID: 2438894
    [No Abstract]   [Full Text] [Related]  

  • 36. Are ABVD and MOPP/ABV truly equivalent for treating Hodgkin's disease at advanced stages?
    Andrieu JM; Colonna P
    J Clin Oncol; 1998 Jun; 16(6):2283. PubMed ID: 9626234
    [No Abstract]   [Full Text] [Related]  

  • 37. Real-life Experience for Integration of PET-CT in the Treatment of Hodgkin Lymphoma in Lebanon.
    Sakr R; Massoud M; Kerbage F; Rached L; Zeghondy J; Akoury E; Nasr F; Chahine G
    Clin Lymphoma Myeloma Leuk; 2017 Jul; 17S():S92-S95. PubMed ID: 28760308
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Patients with stage III/IV Hodgkin's disease in partial remission after MOPP/ABV chemotherapy have excellent prognosis after additional involved-field radiotherapy: interim results from the ongoing EORTC-LCG and GPMC phase III trial. The EORTC Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie.
    Raemaekers J; Burgers M; Henry-Amar M; Pinna A; Mandard A; Monfardini S; Hagenbeek A; Breed W; Carde P; Vovk M; van Hoof A; Thomas J; Noordijk E
    Ann Oncol; 1997; 8 Suppl 1():111-4. PubMed ID: 9187443
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5.
    Sieber M; Tesch H; Pfistner B; Rueffer U; Lathan B; Brosteanu O; Paulus U; Koch T; Pfreundschuh M; Loeffler M; Engert A; Josting A; Wolf J; Hasenclever D; Franklin J; Duehmke E; Georgii A; Schalk KP; Kirchner H; Doelken G; Munker R; Koch P; Herrmann R; Greil R; Anselmo AP; Diehl V
    J Clin Oncol; 2002 Jan; 20(2):476-84. PubMed ID: 11786577
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial.
    Raemaekers JM; André MP; Federico M; Girinsky T; Oumedaly R; Brusamolino E; Brice P; Fermé C; van der Maazen R; Gotti M; Bouabdallah R; Sebban CJ; Lievens Y; Re A; Stamatoullas A; Morschhauser F; Lugtenburg PJ; Abruzzese E; Olivier P; Casasnovas RO; van Imhoff G; Raveloarivahy T; Bellei M; van der Borght T; Bardet S; Versari A; Hutchings M; Meignan M; Fortpied C
    J Clin Oncol; 2014 Apr; 32(12):1188-94. PubMed ID: 24637998
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.